培美曲塞联合顺铂治疗晚期复治性非小细胞肺癌临床观察  

Clinical observation of pemetrexed combined with cisplaton as second-line treatment for advanced non-small cell lung cancer(NSCLC)

作　　者：薛玉保 周学义[1] 史会昌[1] 

机构地区：[1]淮安市第二人民医院肿瘤内科,江苏淮安223002

出　　处：《现代肿瘤医学》2012年第5期973-975,共3页Journal of Modern Oncology

摘　　要：目的:观察培美曲塞联合顺铂方案治疗晚期复治的非小细胞肺癌的疗效和毒副反应。方法:31例既往化疗或靶向治疗失败的晚期非小细胞肺癌患者接受培美曲塞联合顺铂方案化疗,其中培美曲塞500mg/m2加入0.9%氯化钠注射液100ml静脉点滴超过10min;顺铂25mg/m2,静滴1小时,第1-3天,每21d重复,2周期评价疗效。结果:31例患者中,部分缓解(PR)8例,稳定(SD)16例,进展(PD)7例,总有效率为25.81%,临床获益率为77.42%。中位无进展生存期3.1个月,中位生存期8.9个月,1年生存率29.03%(9/31)。主要毒副反应为骨髓抑制,白细胞降低率70.97%,均为1-2度;血小板降低率16.13%,均为1度。结论:培美曲塞联合顺铂方案是一线治疗失败的晚期非小细胞肺癌的理想方案之一。Objective：To investigate the efficacy and toxicities of pemetrexed in combination with cisplaton in previously treated patients with NSCLC.Methods：Thirty one patients of advanced NSCLC who had received targeted therapy or chemotherapy but had progressed,received pemetrexed 500 mg/m2,in 100ml of 0.9%NACL,10 min intervenous drip,cisplaton 25 mg/m2 d1-3,every 21 days.To evaluate efficacy after 2 cycles.Results：Of 31 patients,8 patient were PR,16 patients were SD,7 patients were PD,the overall response rate was 25.81%.The clinical benefit rate was 77.42%.The median time to diease progression was 3.1 months and the median survival time was 8.9 months.The 1-year survival rate was 29.03%.The main toxicity was hematological toxicity.Grade I-II leukopenia was seen in 22 patients（70.97%）.Grade I thrombocytopenia was seen in 5 patients（16.13%）.Conclusion：Pemetrexed in combination with cisplaton is an ideal option for advanced NSCLC had received therapy but had progressed.

关 键 词：培美曲塞 顺铂 晚期非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]